ARZT.Y Stock Overview
Provides products and services for in-store bakery solutions in Europe and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 3/6 |
| Past Performance | 4/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
ARYZTA AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CHF 0.83 |
| 52 Week High | CHF 1.00 |
| 52 Week Low | CHF 0.80 |
| Beta | 1.64 |
| 11 Month Change | -8.03% |
| 3 Month Change | -14.67% |
| 1 Year Change | -10.07% |
| 33 Year Change | 48.33% |
| 5 Year Change | 69.54% |
| Change since IPO | -96.95% |
Recent News & Updates
Recent updates
Shareholder Returns
| ARZT.Y | US Food | US Market | |
|---|---|---|---|
| 7D | 3.5% | 1.9% | 2.2% |
| 1Y | -10.1% | 0.7% | 31.6% |
Return vs Industry: ARZT.Y underperformed the US Food industry which returned 0.7% over the past year.
Return vs Market: ARZT.Y underperformed the US Market which returned 31.7% over the past year.
Price Volatility
| ARZT.Y volatility | |
|---|---|
| ARZT.Y Average Weekly Movement | n/a |
| Food Industry Average Movement | 5.0% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: ARZT.Y's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine ARZT.Y's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2023 | 7,771 | Urs Jordi | www.aryzta.com |
ARYZTA AG provides products and services for in-store bakery solutions in Europe and internationally. It offers pastries, cookies, buns, bread, rolls, artisan loaves, sweet baked goods, morning goods, and savory and other products. The company is also involved in asset management services; and distribution of food products.
ARYZTA AG Fundamentals Summary
| ARZT.Y fundamental statistics | |
|---|---|
| Market cap | US$1.65b |
| Earnings (TTM) | US$76.37m |
| Revenue (TTM) | US$2.23b |
21.5x
P/E Ratio0.7x
P/S RatioIs ARZT.Y overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ARZT.Y income statement (TTM) | |
|---|---|
| Revenue | €2.15b |
| Cost of Revenue | €1.70b |
| Gross Profit | €442.34m |
| Other Expenses | €369.01m |
| Earnings | €73.34m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Mar 03, 2025
| Earnings per share (EPS) | 0.074 |
| Gross Margin | 20.62% |
| Net Profit Margin | 3.42% |
| Debt/Equity Ratio | 53.2% |
How did ARZT.Y perform over the long term?
See historical performance and comparison